Section Arrow
RDHL.NASDAQ
- Redhill Biopharma Ltd
(Financial Status)
Quotes are at least 15-min delayed:2026/05/19 00:50 EDT
Regular Hours
Last
 0.9335
-0.0965 (-9.37%)
Day High 
1.07 
Prev. Close
1.03 
1-M High
1.1 
Volume 
951.27K 
Bid
0.9201
Ask
0.9799
Day Low
0.9 
Open
1.04 
1-M Low
0.7803 
Market Cap 
5.35M 
Currency 美元 
P/E 0.09 
%Yield -- 
10-SMA 1.02 
20-SMA
50-SMA 0.9 
52-W High 3.3099 
52-W Low 0.7101 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-1.10
Enterprise Value
6.25M
Balance Sheet
Book Value Per Share
0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
286.00K
Operating Revenue Per Share
6.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SBFMSunshine Biopharma Inc0.51+0.2259+79.51%-- 
HIMSHims & Hers Health22.29-2.76-11.02%-- 
ESPREsperion Therapeutics3.13+0.01+0.32%-- 
CGCCanopy Growth Corp0.9823-0.0577-5.55%-- 
VTRSViatris16.5+0.02+0.12%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.